Funding for this research was provided by:
U.S. Army (W81XWH-18-2-0040, W81XWH-11-2-0174)
U.S. Army Medical Research and Development Command (W81XWH-18-C-0077)
Bundesministerium für Gesundheit
National Institutes of Health
Received: 26 February 2021
Accepted: 4 August 2021
First Online: 16 August 2021
: All participants provided written informed consent in either German or English. The study was approved by institutional review boards at all collaborating institutions. In the conduct of research where humans are the subjects, the investigators adhered to the policies regarding the protection of human subjects as prescribed by Code of Federal Regulations (CFR) Title 45, Volume 1, Part 46; Title 32, Chapter 1, Part 219; and Title 21, Chapter 1, Part 50 (Protection of Human Subjects). The investigators have also adhered to the policies for protection of human subjects as prescribed in AR 70-25.
: Not applicable.
: CDS reports grants and/or personal fees from AbbVie, Aperion, Eli Lilly, Formycon, Gilead Sciences, MSD, Janssen-Cilag, and GSK/ViiV Healthcare outside the submitted work. The other authors report no potential conflicts of interest.